发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Cardiovascular-kidney-metabolic (CKM) syndrome. 心血管肾代谢综合征。
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.026
Karen M Dwyer, Penelope E Figtree, Katie Oetsch, Alok Gupta
{"title":"Cardiovascular-kidney-metabolic (CKM) syndrome.","authors":"Karen M Dwyer, Penelope E Figtree, Katie Oetsch, Alok Gupta","doi":"10.18773/austprescr.2026.026","DOIUrl":"10.18773/austprescr.2026.026","url":null,"abstract":"<p><p>Cardiovascular-kidney-metabolic (CKM) syndrome recognises the connection between metabolic conditions (particularly obesity, diabetes and metabolic dysfunction-associated fatty liver disease), chronic kidney disease and cardiovascular disease. There is a high and growing prevalence of CKM syndrome. While genetic and epigenetic factors predispose to CKM syndrome, the emergence of disease is heavily influenced by social determinants of health and individual behaviours. The pathophysiology of CKM syndrome is driven by insulin resistance, inflammation, oxidative stress and vascular dysfunction. Urinary albumin:creatinine ratio is a relatively cheap and accessible biomarker of CKM syndrome, which can be used to identify and monitor disease trajectory. Primary and secondary prevention is relevant across the life course. Healthy behaviours, including diet, physical activity, sleep and stress management are important. There are established and emerging drugs that are effective across a range of metabolic conditions and that confer reno- and cardio-protective effects. Remission may be achievable.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"79-83"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intra-articular hyaluronic acid for osteoarthritis. 关节内透明质酸治疗骨关节炎。
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.025
Jeannie Devereaux, Amit Lakkaraju, Zane Sherif, Don Buford, Huai Leng Pisaniello, Shyan Goh, Rachelle Buchbinder
{"title":"Intra-articular hyaluronic acid for osteoarthritis.","authors":"Jeannie Devereaux, Amit Lakkaraju, Zane Sherif, Don Buford, Huai Leng Pisaniello, Shyan Goh, Rachelle Buchbinder","doi":"10.18773/austprescr.2026.025","DOIUrl":"10.18773/austprescr.2026.025","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"104-105"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Capivasertib for locally advanced or metastatic breast cancer. Capivasertib用于局部晚期或转移性乳腺癌
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.021
{"title":"Capivasertib for locally advanced or metastatic breast cancer.","authors":"","doi":"10.18773/austprescr.2026.021","DOIUrl":"10.18773/austprescr.2026.021","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"109-111"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and management of irritable bowel syndrome. 肠易激综合征的诊断和治疗。
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.018
Savannah Morrison, Nicholas Talley
{"title":"Diagnosis and management of irritable bowel syndrome.","authors":"Savannah Morrison, Nicholas Talley","doi":"10.18773/austprescr.2026.018","DOIUrl":"10.18773/austprescr.2026.018","url":null,"abstract":"<p><p>Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterised by recurrent abdominal pain or discomfort that is often related to defaecation or associated with a change in stool frequency or form. IBS is common in Australia and affects women more than men. The exact pathophysiology remains unclear, though it can be multifactorial and relate to gastrointestinal dysmotility, post-infection and microbial changes, and a patient's psychosocial background. A positive clinical diagnosis can be made when the Rome V criteria are met, alarm features are absent and simple screening tests (full blood count, C-reactive protein, coeliac serology) are negative. If alarm features are present, further examination, laboratory testing or imaging may be helpful in assessing for organic pathology. Management involves lifestyle and dietary modifications, and psychological and pharmacological therapies. Pharmacological therapy should be individualised to the patient's IBS subtype and symptoms. Examples of drug classes that are used include antispasmodics, osmotic laxatives, antidiarrhoeal drugs and neuromodulators (tricyclic antidepressants). There is insufficient evidence to support the use of therapies such as probiotics, faecal microbiota transplantation, and mesalamine.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"93-98"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eflornithine for neuroblastoma. 依氟鸟氨酸治疗神经母细胞瘤。
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.022
{"title":"Eflornithine for neuroblastoma.","authors":"","doi":"10.18773/austprescr.2026.022","DOIUrl":"10.18773/austprescr.2026.022","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"112-113"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium valproate: balancing benefits and risks especially in people of childbearing potential. 丙戊酸钠：平衡利益和风险，特别是在生育潜力的人。
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.023
Dan McLaughlin
{"title":"Sodium valproate: balancing benefits and risks especially in people of childbearing potential.","authors":"Dan McLaughlin","doi":"10.18773/austprescr.2026.023","DOIUrl":"10.18773/austprescr.2026.023","url":null,"abstract":"<p><p>Sodium valproate (valproate) is an approved treatment for epilepsy and bipolar disorder in Australia. It is associated with a range of adverse effects that require monitoring and may limit its use. Due to its teratogenicity, valproate should not be prescribed to women of childbearing potential. Lamotrigine or levetiracetam are preferred alternatives in epilepsy. If no alternative is suitable and valproate is prescribed, contraception should be co-prescribed. Concerns have been raised about the potential risk of neurodevelopmental disorders in children born to men taking valproate; although these findings have not been confirmed in robust studies, male patients should be informed of the potential risk.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"84-87"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bulevirtide for hepatitis D infection. 布利韦肽治疗丁型肝炎感染。
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.020
{"title":"Bulevirtide for hepatitis D infection.","authors":"","doi":"10.18773/austprescr.2026.020","DOIUrl":"10.18773/austprescr.2026.020","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"107-108"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stopping antidepressants: when and how. 停止抗抑郁药：何时以及如何停止。
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.019
Katharine A Wallis
{"title":"Stopping antidepressants: when and how.","authors":"Katharine A Wallis","doi":"10.18773/austprescr.2026.019","DOIUrl":"10.18773/austprescr.2026.019","url":null,"abstract":"<p><p>One in seven Australians takes an antidepressant, with around half taking them long-term (over 12 months). Unnecessarily prolonged antidepressant use should be avoided because of the risk of adverse effects. A thorough mental health and medication history should inform whether it is appropriate to attempt to stop an antidepressant. The time to stop may be when the recommended duration of therapy is complete and there is no clinical indication for continued use, or where there are adverse effects that outweigh the benefits. Stopping antidepressants abruptly may precipitate withdrawal symptoms. Withdrawal symptoms may be more likely with longer duration of therapy and with certain antidepressants, such as duloxetine, venlafaxine and paroxetine. Slowly decreasing the antidepressant dose (tapering) can help to minimise withdrawal symptoms. The optimal antidepressant tapering approach is not yet known. Tapering usually involves decreasing the antidepressant dose in smaller decrements as the dose is lowered. In patients at low risk of withdrawal symptoms, guidelines recommend 25 to 50% dose reductions over 2 to 6 weeks (e.g. sertraline 100 mg tapered at 2-weekly intervals to 50 mg, 25 mg, then stop). In patients at higher risk of withdrawal symptoms, and those who have experienced difficulty stopping, smaller dose reductions over many weeks or months, through to very low drug doses (e.g. sertraline 1 mg), may be necessary; this may require compounded or liquid 'mini doses'.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"99-103"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual antihypertensive fixed-dose combinations approved for first-line use on the Pharmaceutical Benefits Scheme. 双重抗高血压固定剂量组合药物福利计划批准一线使用。
IF 4.3
Australian Prescriber Pub Date : 2026-06-01 DOI: 10.18773/austprescr.2026.024
{"title":"Dual antihypertensive fixed-dose combinations approved for first-line use on the Pharmaceutical Benefits Scheme.","authors":"","doi":"10.18773/austprescr.2026.024","DOIUrl":"10.18773/austprescr.2026.024","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 3","pages":"106"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxic interaction between atorvastatin and clarithromycin causing myositis and rhabdomyolysis. 阿托伐他汀和克拉霉素的毒性相互作用引起肌炎和横纹肌溶解。
IF 4.3
Australian Prescriber Pub Date : 2026-04-01 DOI: 10.18773/austprescr.2026.013
Mitchel Hurlbert, Tien Tay, Cameron J Holloway, Laila Girgis
{"title":"Toxic interaction between atorvastatin and clarithromycin causing myositis and rhabdomyolysis.","authors":"Mitchel Hurlbert, Tien Tay, Cameron J Holloway, Laila Girgis","doi":"10.18773/austprescr.2026.013","DOIUrl":"10.18773/austprescr.2026.013","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 2","pages":"68-69"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13095490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147790315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书